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Abstract
Review Article
IntroductIon
Cancer is a leading cause of mortality worldwide. In 2012, 
8.2 million deaths and 14.1 million new cases of cancer were 
reported, among which 57% occurred in Asia, Africa, and Central 
America. It is estimated that the number of new cancer cases 
per year will increase to 23.6 million by 2030.[1,2] According 
to the GLOBOCAN estimates, the third-most common cancer 
worldwide and the second-most common cancer in Europe is 
Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous 
amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to treat cancer, and pharmacokinetic 
evaluations of anticancer drugs are needed. Objectives: The present review examined different delivery systems and methodologies designed 
in recent years to investigate the pharmacokinetics of the anticancer drug, 5-fluorouracil (5-FU). These methodologies highlight how the issues 
of bioavailability, absorption, half-life, targeted neoplastic cell potential, and high therapeutic index of 5-FU are resolved. Results: A number 
of naturally occurring macromolecules such as modified starch, porphyran, peptides, and folic acids have been found to be successful in vitro 
to improve the permeability and retention effect of 5-FU against solid tumors. A promising approach for targeted 5-FU delivery to oncoproteins 
has resulted in a number of potentially sound anticancer nanocomposites. Chitosan nanoparticles loaded with 5-FU have been shown to exhibit 
cytotoxicity equivalent to 5-FU injections against gastric carcinoma. At the level of inter- and intra-molecular interactions, the co-crystal 
approach has been found to be successful against colorectal cancer proteins. Because of the 5-FU ligand-like nature and its metal-binding 
potential, researchers have shifted attention toward the synergistic co-administration of gold complexes with this drug. Conclusions: This study 
highlighted the techniques used to improve the pharmacokinetics of 5-FU and that “nanocarriers” are a promising approach in this field. The 
conclusion is supported by solid evidence.
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colorectal cancer (CRC).[3] Types of cancer treatments available 
include surgery, chemotherapy, radiotherapy, hormone therapy, 
gene therapy, and others. In chemotherapy, anticancer drugs are 
used to destroy cancer cells.[3]
5-fluorouracil (5-FU) is a US Food and Drug Administration 
(FDA)-approved anticancer drug that is used for the treatment 
of various types of solid tumors. However, it has a poor 
pharmacokinetics profile[4], and therefore, it was not the most 
recommended or best-selling anticancer drug from 2014 to 
2017.[5] Nevertheless, 5-FU has been studied extensively in 
parallel with the following top four recommended and best-
selling anticancer drugs: revlimid, rituximab, trastuzumab, and 
bevacizumab. Even though 5-FU is not the most recommended 
anticancer drug,[6] it has been shown to have a promising 
anticancer effect, and improving its pharmacokinetics behavior 
may increase its use.[7]
In addition to poor pharmacokinetics, some chemotherapeutics 
have severe side effects. Designing economical, novel, and 
effective chemotherapies is an important topic in anticancer 
research, in which 5-FU is an excellent example. After approval 
from the FDA in 1962, cancer-causing malignancies have 
been widely treated by fluoropyrimidines, particularly 5-FU.[8] 
After insertion into deoxyribonucleic acid and ribonucleic 
acid,[9] the pyrimidine nucleus induces apoptosis by inhibiting 
thymidylate synthase. Poor tumor cell selectivity and irregular 
distribution in healthy tissues limit the application of 5-FU. 
Using a typical dose of 600 mg/m2/day, tumor cells are exposed 
to rate-limited active metabolites only for a short time. 5-FU 
is cleared quickly after administration due to a short half-life 
of 20 min.[9]
Due to its narrow therapeutic window, it causes severe health 
complications. Therefore, targeted 5-FU therapy in oncologic 
tissues is an important issue to improve its pharmacokinetic 
profile and facilitate its specific accumulation in tumor cells 
with long exposure.[10] A number of clinical trials using different 
strategies have been conducted and shown promising results, 
and some are ongoing to improve the pharmacokinetics of 
5-FU through plasma level dose adjustment,[11] administration 
through the hepatic artery,[12] synergistic formulation,[13] and 
the use of commercial My-5FU PCM™ kits.[14]
To tackle the issues related to 5-FU as discussed above, 
different approaches have been used in recent years including: 
(1) delivery systems (macromolecular carriers and polymeric 
nanocarriers),[15] (2) solid states of 5-FU,[16] and (3) a synergistic 
approach with 5-FU and active anticancer metals.[17] Figure 1 
shows the number of studies conducted from 2009 to 2019 to 
develop techniques which are useful in assessing the problems 
and side effects that hinder the widespread application of 
5-FU.[7] Data from the ISI Web of Science indicated that the 
use of nanocarriers for improving the efficacy of 5-FU is a 
popular choice [Figure 1], and that the synergistic effect of 
5-FU with metals to form complexes is a popular technique 
to evaluate the pharmacokinetics of 5-FU.[7]
This study aimed to briefly review all the techniques that 
have recently been shown to be effective in improving the 
pharmacokinetics of 5-FU, including absorption, sustained 
release, retention time, sorption, dissolution rate, solubility, 
and stability. The findings of this study may be helpful for 
further research on 5-FU.
MacroMolecule carrIers of 5-fluorouracIl
The aforementioned problems have led to the use of conjugates 
of 5-FU with larger molecules to enhance the absorption and 
retention of macromolecular prodrugs.[15] Macromolecular 
prodrugs formed by combining small drug molecules (e.g., 
5-FU) with polymeric carriers can help in the sustained 
release of the therapeutic drugs in vivo, which results in an 
improved half-life.[17] In addition, researchers have designed 
and prepared a prodrug-based conjugate of 5-FU substituted 
with acetic acid at N
1
 (FUAC), with hydroxyethyl-substituted 
starch (HES) through an ester linkage. Hydrolysis experiments 
of these prodrugs have shown the stability and slow release of 
FUAC at pH 5.8. The FUAC/HES conjugates were tarnished 
to active drug in human and mouse plasma with 20.4 h and 
24.6 h half-lives, respectively. The in vitro and in vivo drug 
release results showed that HES is a promising carrier for 
the controlled release of 5-FU and its derivatives.[18] Other 
studies have shown associations between 5-FU and many 
macromolecules, including pectin,[19] porphyrin, porphyran,[19] 
and folic acid.[20] Another prodrug was recently reported, 
5-FU-1-acetic acid-polyethylene glycol-allyl glycidyl ether-
mercaptoethanol (5-FA-PAE),[21] and 5-FA, a derivative 
of 5-FU, was used with conjugation of the derivative with 
macromolecules to synthesize 5-FA-PAE. The newly designed 
prodrug evaluated in vitro and in vivo for pharmacokinetics 
and antitumor effects, the results were promising. In vivo 
antitumor experimental results of drug (5-FU), derivative (5-
FA), saline solution, and prodrug (5-FA-PAE) revealed that 
this prodrug could transport the drug to malignant cells with 
higher antitumor potential [Figure 2].
Porphyran, a sulfated galactan isolated from Porphyra 
haitanensis (red algae), has shown numerous potent biological 
actions along with anticancer potential. A water-soluble 
macromolecular prodrug was prepared by fixing 5-FU at the 6th 
position of porphyran, and the pharmacokinetics showed a slow 
release with reduced toxicity of 5-FU. The antineoplastic and 
immunomodulation actions on transplanted S180 tumor mice 
with low-molecular-weight porphyran conjugated with 5-FU 
showed enhanced antitumor activity and immunocompetence 
that were impaired by 5-FU.[22]
In 2017, a novel conjugate of 5-FU with poly (amidoamine) 
(PAMAM)[4] was used to deliver drugs to targeted cervical 
cancer oncoproteins. The interactions between E6/E7 
oncoproteins and the PAMAM/5-FU conjugate were 
investigated through molecular docking, and higher affinity 
was seen for the oncoprotein than for 5-FU. The authors also 
confirmed that this material was less toxic by hematological 
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analysis in female mice with cervical cancer. These results 
provide evidence that the newly designed PAMAM/5-FU 
macromolecular conjugate is a latent entrant against cervical 
cancer [Table 1a].
PolyMerIc nanocarrIers of 5-fluorouracIl
There is currently great interest in the development of 
innovative treatments for drug delivery to the site of action. 
Polymeric nanoparticles (NPs) are emerging carriers in this 
regard. These nanocarriers are synthesized by loading 5-FU 
on nanoparticles for the selective delivery of the drug to 
cancerous cells.[23] Another study also showed promising 
results of loading 5-FU conjugates on nanoparticles.[24] The 
mechanism used for 5-FU conjugate-loaded nanocarrier 
synthesis is explained in Figure 3. The mechanism consists 
of two steps namely (1) synthesis of nanoparticles (2) and 
loading of drug conjugate on the nanoparticles. This new 
approach is used to improve drug absorption and to protect 
from fast metabolism and degradation in the small intestine and 
stomach. In 2014, Tummala et al.[25] prepared enteric-coated 
chitosan polymeric nanoparticles (138–149 nm) loaded with 
5-FU (48%–69%) and delivered them directly to the large 
bowel to prevent degradation by gastric pH. These particles 
were synthesized using a solvent evaporation emulsification 
method, which displayed better drug emancipation and in vitro 
82% emancipation in a controlled manner from 4 to 24 h.
Using an ionic gelation method in 2016, Shaima et al.[26] 
prepared 5-FU-loaded chitosan nanoparticles (CNPs) and 
determined their antineoplastic potentials against liver cancer 
cell lines. These particles exhibited cytotoxicity with an IC
50
 
value of 49.50 µg/mL. The sustained release drug properties 
of biodegradable nano drug-transporting methodologies are 
used to enhance the chemotherapeutic agent’s retention time 
in the body. CNP-based drug-transporting systems can carry 
the drug to the site of action with improved bioavailability, 
plasma half-life, and anticancer potentials [Table 1b].
Similar to Shaima’s group, another study[30] was conducted in 
which CNPs loaded with 5-FU (5-FU-CNPs) were prepared 
using an ionic gelation method in a 1:1 mass ratio. The 
nanoparticles (280 nm) possessed the highest drug loading. 
In vitro experiments/studies showed the controlled release of 
the drug, and its cytotoxicity against gastric cancer cells was 
comparable to that of 5-FU injections.
Pectin-based nanoparticles (PNPs) were synthesized in 
one study to deliver 5-FU specifically to hepatocellular 
carcinoma, due to galactose residues present in the polymer 
assembly.[31] These residues showed selectivity for cancer 
cells due to their targeting ligand abilities. The particles had 
a diameter of 300 nm and were synthesized in an aqueous 
medium comprising Ca2+ and CO
3
2− ions, with the drug-
loading content of 24.8%. Cytotoxicity analysis of 5-FU-PNPs 
performed against cell lines of HepG2 and A549 indicated 
better potency in killing cancer cells with the overexpression 
of asialoglycoprotein receptors compared to the free drug. 
Furthermore, an in vivo study of pharmacokinetics in rats 
confirmed that 5-FU-PNPs in circulatory fluids have a 
longer half-life than the free drug. In summary, pectin-based 
drug delivery systems may be promising platform against 
hepatocellular carcinoma. To improve the nonspecificity of 
5-FU, Liu et al.[24] prepared 5-FU-loaded hyaluronic acid (HA)-
conjugated silica nanoparticles (HSNPs). These particles were 
approximately 130 nm and showed sustained release of 5-FU 
for 120 h. Cytotoxic studies against colon cancer cells revealed 
that, after 1 day of incubation, the IC
50
 values of 5-FU/HSNPs 
and 5-FU/SNP were 0.65 and 2.80 µg/mL, respectively. Hence, 
HA-conjugated nanoparticles may be more effective as an 
apoptosis inducer in cancer cells. Furthermore, 5-FU/HSNPs 
exhibited cell apoptosis of 45% compared to only 20% for 
5-FU/silica nanoparticles (SNP). Therefore, 5-FU/HSNPs may 
be an active drug delivery system for colon cancer treatment.
Figure 1: Comparisons between the methodologies opted for 
pharmacokinetic improvement of 5-FU from 2009 to 2019[7]
Figure 2: Antitumor effects of saline, 5-fluorouracil prodrug, 5-fluorouracil 
derivative, and drug on tumor-bearing mice[21]
Figure 3: Assembly of 5-fluorouracil loaded nanopar ticle and 
5-fluorouracil conjugate-loaded nanoparticle[24]
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In recent years, conventional chemotherapy has not been very 
effective in CRC treatment because the drug does not get into 
the tumor site in effective therapeutic concentrations. Therefore, 
researchers have developed site-specific carriers/transporters to 
selectively deliver the drug in the colon region. Eudragit S100-
coated citrus pectin nanoparticles (E-CPNPs) were formulated 
for colon-specific routing of 5-FU.[32] Citrus pectin plays the role 
of a ligand for galectin-3 receptors overexpressed in colon cancer 
cells. Selective drug release was observed in in vitro studies for 
E-CPNPs in the colonic region, which showed >70% after 1 
day. The cytotoxicity assay against HT-29 cells demonstrated 
a 1.5-fold increase in the cytotoxic potential of NPs compared 
to 5-FU solution. Therefore, it is a complex methodology in 
terms of receptor-mediated uptake using E-CPNPs for effective 
chemotherapy against CRC with improved safety. In 2016, 
Sağir et al.[33] prepared super paramagnetic magnetite zeolite 
nanocomposites (MZNCs) and further loaded them with 5-FU. 
These nanocomposites showed a sustained release without 
bursts and evaluated their cytotoxic effects against human 
gastric carcinoma (AGS) cells. Apoptosis studies indicated the 
loss of cell membrane integrity, and the authors concluded that 
5-FU-loaded MZNCs displayed concentration-dependent cell 
proliferation inhibition against AGS cells.
Onivyde, PEP02 or MM-398, is a nano liposomal form of 
irinotecan, which was approved in October 2015 by the US 
FDA as a combination regimen for the treatment of resistant 
metastatic pancreatic cancer associated with gemcitabine-based 
chemotherapy.[34] It has recently been investigated in Phase II 
and Phase III clinical trials against various cancers, including 
pancreatic, esophago-gastric, and CRC. It has attracted 
attention because it can: (i) enhance drug pharmacokinetics 
profile, increase encapsulation of the drug, (iii) improve 
loading efficiency, (iv) protect the drug in the active lactone 
form through its nano formulation, (v) prolong circulation 
time, (vi) control drug release, (vii) reroute the drug from toxic 
sites, gastrointestinal tract, and (viii) enhance permeability and 
retention effect of the drug and reduce host toxicity.[35] In a 
clinical trial, a combination of Onivyde with 5-FU/leucovorin 
(5-FU/LV) [Figure 4] confirmed an enhancement in median 
overall survival (OS), which means that the survival rate 
increased in the patients who received the regimen compared 
with the 5-FU/LV alone group.[36] The good results may be 
because of the improvement in the pharmacokinetics of 5-FU 
with Onivyde.[34] This combination therapy has become a 
standard first-line therapy in the treatment of mCRC.[37]
antItuMor solId states of 5-fluorouracIl
Co-crystalline states are well-designed, synthesized structures 
with preferred inter- and intra-molecular interactions (hydrogen 
bonding). Co-crystallization is a process of formulation and 
elucidation of crystalline systems of active pharmaceutical 
ingredients (APIs) with improved sorption, dissolution rate, 
solubility, and stability toward degradation. A number of 
co-crystals containing 5-FU as the active component have 
been manufactured through grinding and a normal solution 
method. Docking studies have been used to investigate the 
potential of novel co-crystals against CRC target proteins, 
and the results have shown promising antitumor activity. 
Nadzri et al. prepared[38] solid states of 5-FU with bases, 
i.e., urea, thiourea, 2,2’–bipyridine, and 4,4’-bipyridine. 
Following this, Mohana et al. prepared[16] co-crystals of 5-FU 
with halogenated substituted thiophene carboxylic acids and 
substituted nitrobenzoic acid. However, they did not evaluate 
the synthesized solid states for their anticancer actions.
synergIsM of 5-fluorouracIl wIth Metal 
coMPlexes
Metal complexes have been of great interest to oncologists 
since the 1970s, after the development/application of cisplatin 
Table 1a: Delivery systems of 5-fluorouracil and 5-fluorouracil conjugate: Macromolecule carriers
Macromolecule carrier Methodology Significance Study ID (reference)
FUAC/HESa Prodrug Stable and slow release of drug at pH 5.8 [17]
5-FU/PAMAMb Prodrug Selective delivery of drug to cervical oncoproteins [4]
5-FA-PAEc Prodrug Improved loading of drug, half-life, bioavailability, and in vivo antitumor potentials [21]
5-FU: 5-fluorouracil, FUAC/HESa: 5-FU-1-acetic acid/hydroxyethyl substituted starch, 5-FU/PAMAMb: 5-FU/polyamidoamine, 5-FA-PAEc: 5-FU-1-acetic 
acid-polyethylene glycol-allyl glycidyl ether-mercaptoethanol
Table 1b: Delivery systems of 5-fluorouracil and 5-fluorouracil conjugate: Chitosan-based nanocarriers
Nanocarrier Methodology Significance Study ID (reference)
5-FU/curcumin thiolated CSNPsd Ionic cross-linking Improved bioavailability, plasma half-life, and anticancer 
potentials
[28]
5-FU magnetic CSNPs Reverse microemulsion 
method
Slow release of drug with significant anticancer actions [29]
5-FU loaded CS/Ag/MWCNTe Chemical method Prolonged and sustained release of drug with IC
50
 50 µg/mL [30]
5-FU-CSNPs Ionic gelation Inhibitory effect against SGC-7901 cancer cell was similar to 
5-FU injection
[27]
5-FU: 5-fluorouracil, CSNPsd: Chitosan nanoparticles, MWCNTe: Multiwalled carbon nanotube
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(platinum-based) as an anticancer agent. Researchers have 
subsequently studied the antiproliferative actions of other 
metals including silver and shown their potential for treatment. 
Coordination chemistry can explain the ligand-like nature of the 
5-FU pyrimidine ring that helps binding to metal ions. Based 
on this ligand metal binding and the respective anticancer 
potential, recent research has investigated the binding of silver 
(I) metal ions[39] with 5-FU to study the enhanced anticancer 
and pharmacokinetic potentials. The synthesized complex, 
characterized by spectroscopy techniques, was evaluated 
for its antiproliferative activity and was shown to be active. 
Estimation of the antiproliferative activity of 5-FU and 5-FU/
Ag (I) ion complex against ovarian multidrug-resistant and 
colon cancer cell lines was also performed. The complex 
showed 50% growth inhibition values (GI
50
) of 0.34 µg/mL 
for colon cells and 0.36 µg/mL for multidrug-resistant ovarian 
cells. The 50% growth inhibition values of free 5-FU and 
cisplatin against multidrug-resistant ovarian cells were 2.3 
and 2.49 µg/mL, respectively, compared to 0.42 µg/mL and 
5.11 µg/mL for colon cells, respectively. Moreover, various 
studies[40-42] have shown that a wide range of gold complexes 
display antiproliferative properties against a range of tumor 
cells. Blasco et al.[3] prepared novel gold (I) thiolate complexes 
and investigated the synergistic effect of the co-administration 
of these gold complexes, and the results showed good cytotoxic 
effects with 5-FU. They also confirmed a reduction in 5-FU 
dose of up to forty times to achieve an equivalent effect as with 
5-FU alone [Table 1c].
In addition to 5-FU metal complexes, other researchers[43] 
have synthesized 5-FU-loaded copper (I)-thiourea and iron 
(III)-fumaric acid metal organic gels (MOGs). The authors 
reported that the drug release for the synthesized MOGs was 
higher at pH 5 than at pH 7.4. Therefore, 5-FU in combination 
with a metal in the form of complexes or MOGs appears to 
be an encouraging technique to improve pharmacokinetics.
future PersPectIves
Currently, 5-FU is used for the treatment of solid malignant 
tumors of the stomach, pancreas, colon, breast, neck, head, 
cervix, urinary bladder, ovarian, prostate, and oropharynx, with 
a response rate of 10%–30%. 5-FU has been extensively studied 
over the last decade. However, due to the pharmacokinetic 
issues explained above, the main challenge is to make 5-FU 
a highly recommended anticancer drug. This study showed 
the side effects that must be addressed to enhance 5-FU 
cancer therapeutics. The results confirm that the development 
of pharmacokinetics of 5-FU is crucial and has become an 
important part of anticancer drug research because more potent 
and safer drugs are needed for cancer chemotherapy. This study 
evaluated and compared different options for successfully 
transporting 5-FU to cancerous cells as shown in various studies 
conducted in the last decade [Figure 1]. The most successful 
approach was the design of 5-FU-loaded nanocarriers. In 
summary, this study could be helpful for future research 
conducted to evaluate how to increase the anticancer potential 
of 5-FU and minimize the side effects and related issues.
Figure 4: A combination regimen of Onivyde + 5-fluorouracil/leucovorin
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conclusIons
This study focused on the currently available methodologies 
designed to overcome the pharmacokinetic issues with 5-FU, 
which limit its therapeutic efficiency. Low bioavailability, 
absorption, half-life, targeted neoplastic cell potential, and 
therapeutic index are the major pharmacokinetic flaws 
associated with 5-FU. The most promising approach is 
nanocarrier synthesis for 5-FU loading due to improved drug 
absorption, protection from fast metabolism, and degradation 
in the small intestine and stomach. Based on the results for 
reducing the dose of 5-FU through a metal complex synergistic 
approach, we suggest that this technique should be explored 
further to improve the safety and anticancer potential of 5-FU. 
The promising results associated with the reported techniques 
are summarized as follows:
1. Macro- and nano-particle delivery systems of 5-FU have 
shown very promising results in the improvement of 
absorption, sustained release, and retention time of the 
drug in targeted cells
2. Onivyde, a nanoliposomal form of irinotecan in 
combination with 5-FU/leucovorin, showed an 
improvement in median OS
3. 5-FU co-crystal API showed improved sorption, 
dissolution rate, solubility, and stability toward 
degradation
4. The synergistic effect of 5-FU with gold complexes also 
showed positive results.
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